Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial

• Published in: European journal of heart failure Vol. 23; no. 8; pp. 1313 - 1321
• Main Authors: Voors, Adriaan A., Mulder, Hillary, Reyes, Eugene, Cowie, Martin R., Lassus, Johan, Hernandez, Adrian F., Ezekowitz, Justin A., Butler, Javed, O'Connor, Christopher M., Koglin, Joerg, Lam, Carolyn S.P., Pieske, Burkert, Roessig, Lothar, Ponikowski, Piotr, Anstrom, Kevin J., Armstrong, Paul W.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01.08.2021
• Subjects: Aged; Estimated glomerular filtration rate; Female; Glomerular Filtration Rate; Heart failure; Heart Failure - drug therapy; Heart Failure - epidemiology; Heart failure with reduced ejection fraction; Heterocyclic Compounds, 2-Ring; Humans; Kidney - physiology; Male; Pyrimidines; Renal function; Stroke Volume; Treatment Outcome; Victoria Trial; Heart failure; Heart failure with reduced ejection fraction; Renal function; Estimated glomerular filtration rate

Aims Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m2. We evaluated the re...